UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): July 9,
2021
AzurRx BioPharma, Inc.
(Exact name of registrant as specified in its
charter)
|
|
|
|
|
|
|
Delaware
|
|
001-37853
|
|
46-4993860
|
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
777 Yamato Road, Suite 502
Boca Raton, Florida
|
|
33431
|
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrant’s telephone number, including area code: (561)
589-7020
Not Applicable
(Former name or former address, if changed since last
report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
[
] Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
[
] Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)
[
] Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
[
] Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the
Act:
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which
registered
|
|
Common
Stock, par value $0.0001 per share
|
AZRX
|
Nasdaq
Capital Market
|
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (17
CFR §230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (17 CFR §240.12b-2 of this
chapter).
Emerging growth company [X]
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange
Act. ☐
Item 5.02 Departure of Directors or Certain Officers; Election of
Directors; Appointment of Certain Officers; Compensatory
Arrangements of Certain Officers.
On
July 9, 2021, the Board of Directors (the “Board”) of
AzurRx BioPharma, Inc. (the “Company”) approved an
increase in the annual base salary of James Pennington, the
Company’s Chief Medical Officer, from $260,000 to $425,000
per year, effective July 1, 2021, plus an additional one-time
salary payment of $27,500. The Board also approved an award of
100,000 options (the “Options”) to purchase shares of
the Company’s common stock, par value $0.0001 per share (the
“Common Stock”). The Options were granted in accordance
with the terms of the Company’s 2020 Omnibus Equity Incentive
Plan, as amended and restated. The Options have an exercise price
of $0.75, which is the closing price of the Common Stock on July 9,
2021, and will vest in 36 equal monthly installments over three
years beginning on the date of grant.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
July 9,
2021
|
AzurRx BioPharma, Inc.
By:
/s/
Daniel Schneiderman
Name:
Daniel Schneiderman
Title:
Chief Financial Officer
|